Comparing the current results to its competitors, Innoviva Inc reported Revenue increase in the 2 quarter 2026 by 28.39 % year on year. The sales growth was above Innoviva Inc 's competitors' average revenue growth of 13.59 %, achieved in the same quarter.
Innoviva Inc , slower than the average decrease reported by the company's competitors of -50.7 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -50.7 %
Innoviva Inc 's Comment on Competition and Industry Peers
RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol) and ANORO ELLIPTA (umeclidinium/vilanterol) are positioned to compete with several approved bronchodilator drugs and drug candidates for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Competitors include Advair/Seretide Diskus/HFA marketed by GSK, Symbicort marketed by AstraZeneca, AirDuo Respiclick marketed by TEVA, Spiriva Handihaler and Spiriva Respimat marketed by Boehringer Ingelheim, and Dulera. The introduction of generic equivalents has historically led to significant sales declines for branded products. The U.S. Food and Drug Administration (FDA) issued draft guidance documents in 2016 and 2020 addressing the active ingredients in RELVAR/BREO ELLIPTA and ANORO ELLIPTA, respectively.
November 7, 2024
Innoviva Inc. Reports Third Quarter 2024 Financial Results: A Mixed Bag for Investors Innoviva Inc. (NASDAQ: INVA) has recently published its third quarter 2024 financial results, providing investors with a snapshot of its performance and strategic advancements in the biopharmaceutical sector. The company s stock is currently trading at $19.92 and has shown a positive trend this month, outperforming the general market with a 3.38% gain. However, when considering its year-to-date performance, Innoviva s shares have risen only 21.69%, which falls short of the broader market s impressive 24.87% growth.The nuanced financial results from Innoviva reveal both achievements and challenges that the company faces movi...
November 6, 2024
This article aims to provide a summary of the recent financial results for Innoviva, Inc. (NASDAQ: INVA) for the third quarter of 2024, along with an analysis of the company s recent progress within the pharmaceutical sector. These results reflect Innoviva s diversified interests and strategic positioning in the market. Innoviva, Inc. based in Burlingame, California, has solidified its presence as a diversified holding company, maintaining a core portfolio of royalty interests alongside a specialized focus on critical care and infectious diseases through its subsidiary, Innoviva Specialty Therapeutics (IST). As of the close of trading on September 30, 2024, the company has reported its financial results ...
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
Bicycle Therapeutics Plc's business model is centered around the development and commercialization of novel therapeutics using its proprietary bicyclic peptide platform.
Tenax Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing products for critical care patients with cardiovascular and pulmonary diseases. Their business model revolves around conducting research and clinical trials to bring innovative therapies to market. They generate revenue primarily by licensing their products to other pharmaceutical companies or through direct sales to hospitals and healthcare providers.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Sources:
Innoviva Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Innoviva Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
